Anticancer Res

1. MASUDA H, Amemiya Y, Yagisawa N, Arai T, et al
   Association Between Acute Kidney Injury and the Trendelenburg Position Angle During Robot-assisted Radical Prostatectomy.
   Anticancer Res. 2024;44:1767-1772.
   

   >> Share

   
   
2. KASHIWAGI E, Kawahara T, Kinoshita F, Shiota M, et al
   The Role of Adipocytokines and their Receptors in Prostate Cancer: Adiponectin May Protect Against Progression.
   Anticancer Res. 2024;44:1369-1376.
   

   >> Share

   
   
3. CHANG CC, Chiou JK, Lin CJ, Lu K, et al
   Machine-learning Algorithm-based Risk Prediction and Screening-detected Prostate Cancer in A Benign Prostate Hyperplasia Cohort.
   Anticancer Res. 2024;44:1683-1693.
   

   >> Share

   
   

   
   BJU Int

4. PAK JS, Huang R, Huang WC, Lepor H, et al
   Interaction of patient age and high-grade prostate cancer on targeted biopsies of MRI suspicious lesions.
   BJU Int. 2024 Mar 27. doi: 10.1111/bju.16341.
   

   >> Share

   
   

   
   BMC Urol

5. LAMA DJ, Thomas K, Vernez SL, Okunowo O, et al
   Minimally invasive cytoreductive radical prostatectomy, exploring the safety and feasibility of a single-port or multi-port robotic platform.
   BMC Urol. 2024;24:72.
   

   >> Share

   
   
6. KRAUSEWITZ P, Buttner T, von Danwitz M, Weiten R, et al
   Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center.
   BMC Urol. 2024;24:71.
   

   >> Share

   
   
7. ALBO G, Gallioli A, Ripa F, De Lorenzis E, et al
   Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique.
   BMC Urol. 2024;24:64.
   

   >> Share

   
   

   
   Cancer

8. SOLANKI AJ, Kamrava M, Posadas EM, Freedland SJ, et al
   A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.
   Cancer. 2024 Mar 26. doi: 10.1002/cncr.35285.
   

   >> Share

   
   
9. PEPPONE LJ, Kleckner AS, Fung C, Puzas JE, et al
   High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.
   Cancer. 2024 Mar 23. doi: 10.1002/cncr.35275.
   

   >> Share

   
   

   
   Cancer Res

10. SHU F, Liu H, Chen X, Liu Y, et al
    m6A modification promotes EMT and metastasis of castration-resistant prostate cancer by upregulating NFIB.
    Cancer Res. 2024 Mar 27. doi: 10.1158/0008-5472.CAN-23-1954.
    

    >> Share

    
    

    
    Clin Cancer Res

11. DESAI KB, Serritella AV, Stadler WM, O'Donnell PH, et al
    A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
    Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3636.
    

    >> Share

    
    

    
    Eur J Radiol

12. QUENTIN M, Boschheidgen M, Radtke JP, Spohn F, et al
    MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer.
    Eur J Radiol. 2024;175:111436.
    

    >> Share

    
    

    
    Eur Radiol

13. GIROMETTI R, Giganti F
    Active surveillance of prostate cancer: MRI and beyond.
    Eur Radiol. 2024 Mar 28. doi: 10.1007/s00330-024-10717.
    

    >> Share

    
    

    
    Eur Urol

14. BURGER M
    Re: First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Pro
    Eur Urol. 2024 Mar 22:S0302-2838(24)02205-X. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
15. DE MEERLEER G, Joniau S, Benijts J, Rans K, et al
    Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not.
    Eur Urol. 2024 Mar 22:S0302-2838(24)02238-3. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
16. WINDISCH O, Valerio M
    Re: Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02208-5. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
17. WASSERSUG RJ, Schellhammer PF, Wibowo E
    Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02233-4. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
18. LOGOTHETIS CJ, Hahn AW
    Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024
    Eur Urol. 2024 Mar 26:S0302-2838(24)02240-1. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    

    
    Int J Cancer

19. STROMBERG U, Berglund A, Carlsson S, Thellenberg Karlsson C, et al
    Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34932.
    

    >> Share

    
    

    
    Mod Pathol

20. IRMAKCI I, Nateghi R, Zhou R, Vescovo M, et al
    Tissue Contamination Challenges the Credibility of Machine Learning Models in Real World Digital Pathology.
    Mod Pathol. 2024;37:100422.
    

    >> Share

    
    

    
    Oncogene

21. YI Q, Han X, Yu HG, Chen HY, et al
    SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
    Oncogene. 2024 Mar 26. doi: 10.1038/s41388-024-02944.
    

    >> Share

    
    

    
    PLoS One

22. CHEN LC, Yang HJ, Yu BH, Lee MS, et al
    Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
    PLoS One. 2024;19:e0300391.
    

    >> Share

    
    

    
    Prostate

23. SHAHAIT M, Hakansson AK, Daniel RE, Hosny K, et al
    Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer.
    Prostate. 2024 Mar 27. doi: 10.1002/pros.24684.
    

    >> Share

    
    
24. MAHON KL, Sutherland SI, Lin HM, Stockler MR, et al
    Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
    Prostate. 2024 Mar 27. doi: 10.1002/pros.24691.
    

    >> Share

    
    
25. DWINA Y, Zaid LSM, Saraswati M, Rachmadi L, et al
    CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration-resistant prostate cancer.
    Prostate. 2024 Mar 25. doi: 10.1002/pros.24690.
    

    >> Share

    
    
26. ONAL C, Guler OC, Erbay G, Elmali A, et al
    The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer.
    Prostate. 2024 Mar 25. doi: 10.1002/pros.24693.
    

    >> Share

    
    
27. QAZI SU, Altaf Z, Zafar M, Tariq MA, et al
    Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis.
    Prostate. 2024;84:525-538.
    

    >> Share

    
    
28. ROMANO L, Napolitano L, Crocetto F, Sciorio C, et al
    Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms.
    Prostate. 2024;84:513-524.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share